Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies02:49

Cancer Therapies

8.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.5K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Tumor Progression02:07

Tumor Progression

6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma.

HemaSphere·2026
Same author

Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment response.

Nature communications·2026
Same author

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing.

HemaSphere·2026
Same author

Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

Clinical pharmacology and therapeutics·2026
Same author

High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Haematologica·2026

Related Experiment Video

Updated: Oct 18, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K

Roadmap to cure multiple myeloma.

Paula Rodriguez-Otero1, Bruno Paiva2, Jesús F San-Miguel2

  • 1Department of Hematology, Clinica Universidad de Navarra, IDISNA, Pamplona, Spain; CIBERONC CB16/12/00369, Spain.

Cancer Treatment Reviews
|October 1, 2021
PubMed
Summary

Achieving a cure for multiple myeloma requires a strategic approach. This involves understanding disease progression, targeting minimal residual disease (MRD), and early intervention for high-risk patients.

Keywords:
CureEarly detectionEarly interventionEarly rescue interventionMultiple Myeloma

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.8K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K

Related Experiment Videos

Last Updated: Oct 18, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.8K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K

Area of Science:

  • Hematology
  • Oncology
  • Cancer Research

Background:

  • Multiple myeloma treatment has advanced, improving response and survival rates.
  • Despite progress, relapse and lack of cure remain significant challenges for patients.

Purpose of the Study:

  • To propose a five-strategy roadmap for achieving a cure for multiple myeloma.
  • To outline a research agenda focusing on novel therapeutic targets and treatment paradigms.

Main Methods:

  • Reviewing current knowledge on multiple myeloma pathogenesis, including circulating tumor cells and minimal residual disease (MRD) clones.
  • Defining undetectable MRD as a new therapeutic endpoint using high-sensitivity techniques.
  • Exploring early detection and intervention strategies for high-risk smoldering myeloma.
  • Investigating the use of highly active treatment regimens in standard-risk patients.
  • Examining experimental therapies for newly diagnosed high-risk multiple myeloma with early rescue interventions.

Main Results:

  • Increased understanding of disease pathogenesis, particularly the role of circulating tumor cells and MRD clones.
  • Establishment of undetectable MRD as a key therapeutic goal.
  • Potential for early intervention in high-risk smoldering myeloma to delay progression and improve cure rates.
  • Identification of optimal treatment strategies for both standard-risk and high-risk newly diagnosed patients.

Conclusions:

  • A multi-pronged strategy focusing on deeper biological insights, novel endpoints, and timely interventions is crucial for multiple myeloma cure.
  • Early detection and treatment of high-risk precursor conditions may significantly improve long-term outcomes.
  • Eradicating all tumor clones to achieve sustained MRD negativity is the ultimate goal for a cure.